ES2029269T5 - Una formulacion de liberacion lenta. - Google Patents

Una formulacion de liberacion lenta.

Info

Publication number
ES2029269T5
ES2029269T5 ES87301231T ES87301231T ES2029269T5 ES 2029269 T5 ES2029269 T5 ES 2029269T5 ES 87301231 T ES87301231 T ES 87301231T ES 87301231 T ES87301231 T ES 87301231T ES 2029269 T5 ES2029269 T5 ES 2029269T5
Authority
ES
Spain
Prior art keywords
water
soluble
granules
released
slowly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87301231T
Other languages
English (en)
Other versions
ES2029269T3 (es
Inventor
Alan Rhodes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethical Pharmaceuticals Ltd
Original Assignee
Ethical Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10592976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2029269(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ethical Pharmaceuticals Ltd filed Critical Ethical Pharmaceuticals Ltd
Application granted granted Critical
Publication of ES2029269T3 publication Critical patent/ES2029269T3/es
Publication of ES2029269T5 publication Critical patent/ES2029269T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UNA FORMULA QUE SE LIBERA LENTAMENTE PARA SER ADMINISTRADA A HUMANOS O ANIMALES, COMPRENDIENDO GRANULOS PRIMARIOS QUE CONTIENEN UN INGREDIENTE ACTIVO Y ESTAN EN UN ELEMENTO SECUNDARIO (2) DE UN MATERIAL SOLUBLE EN EL AGUA QUE SE LIBERA LENTAMENTE, LOS GRANULOS (1) COMPRENDEN PARTICULAS (3) CONTENIENDO LOS INGREDIENTES ACTIVOS Y EN UN ELEMENTO PRIMARIO (4) DE UN MATERIAL QUE SE LIBERA LENTAMENTE SOLUBLE EN EL AGUA. OPCIONALMENTE LA FORMULA COMPRENDE UNA FASE ENLAZADORA (5) DE UN MATERIAL INSOLUBLE QUE SE LIBERA LENTAMENTE QUE TIENE EMBEBIDOS DENTRO DE EL GRANULOS SECUNDARIOS (6) COMPRENDIENDO EL ELEMENTO SECUNDARIO (2) CONTENIENDO LOS GRANULOS DEL ELEMENTO PRIMARIO (1). EL MATERIAL SOLUBLE EN EL AGUA PUEDE SER UN POLISACARIDO Y METILCELULOSA DE BAJA VISCOSIDAD ES EJEMPLIFICADA, ASI COMO ALGINATO Y GELATINA.
ES87301231T 1986-02-13 1987-02-12 Una formulacion de liberacion lenta. Expired - Lifetime ES2029269T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB08603523A GB2186485B (en) 1986-02-13 1986-02-13 Slow release formulation

Publications (2)

Publication Number Publication Date
ES2029269T3 ES2029269T3 (es) 1992-08-01
ES2029269T5 true ES2029269T5 (es) 1999-07-01

Family

ID=10592976

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87301231T Expired - Lifetime ES2029269T5 (es) 1986-02-13 1987-02-12 Una formulacion de liberacion lenta.

Country Status (14)

Country Link
US (1) US4880830A (es)
EP (1) EP0235986B2 (es)
JP (1) JPH0655669B2 (es)
AT (1) ATE64849T1 (es)
DE (1) DE3771091D1 (es)
DK (1) DK175055B1 (es)
ES (1) ES2029269T5 (es)
FI (1) FI91482C (es)
GB (1) GB2186485B (es)
GR (2) GR3002822T3 (es)
IE (1) IE59451B1 (es)
NO (1) NO175240C (es)
PH (1) PH25347A (es)
ZA (1) ZA871030B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
IL96311A (en) † 1989-12-01 1995-05-26 Abbott Lab Medications with delayed release
JP3011752B2 (ja) * 1990-10-23 2000-02-21 フロイント産業株式会社 徐放性製剤およびその製造方法
US5380535A (en) * 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
ES2202302T3 (es) * 1991-05-28 2004-04-01 Mcneil-Ppc, Inc. Composicion masticable que libera un farmaco.
DE4119306C2 (de) * 1991-06-12 1996-05-30 Wheli Inter Ag Organische Rohstoffe, Zwischen- und Endprodukte für die Ernährung und zur Verwendung für technische Zwecke, die Vitalstoffe enthalten
DE4122591C1 (en) * 1991-07-08 1993-02-18 Roland 8012 Ottobrunn De Bodmeier Producing microcapsules of water insoluble polymer and active agent - includes dissolving or dispersing active agent in aq. polymer contg. gellable assistants
US5356629A (en) * 1991-07-12 1994-10-18 United States Surgical Corporation Composition for effecting bone repair
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
WO1996010996A1 (en) * 1993-07-21 1996-04-18 The University Of Kentucky Research Foundation A multicompartment hard capsule with control release properties
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5938990A (en) * 1994-07-01 1999-08-17 Roche Vitamins Inc. Encapsulation of oleophilic substances and compositions produced thereby
DE4426396A1 (de) * 1994-07-26 1996-02-01 Ulrich Prof Dr Zimmermann Verfahren zur Herstellung konzentrierter Lösungen von mikroverkapselten Zellen oder von suspendierten Wirkstoffen in mikroverkapselter Form
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
JP3628809B2 (ja) * 1996-06-10 2005-03-16 アルケア株式会社 薬剤徐放性医療用配合物及びその製造方法
US20030100532A1 (en) * 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
IN186245B (es) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
JP2001522833A (ja) 1997-11-10 2001-11-20 ジー・ディー・サール・アンド・カンパニー 多剤耐性を治療するためのアルキル化イミノ糖類の使用
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
EA004705B1 (ru) 1998-02-12 2004-06-24 Дж.Д.Серл Энд Ко. Применение n-замещенных 1,5-дидезокси-1,5-имино-d-глюцитных производных для лечения инфекций, вызываемых вирусами гепатита
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
EP1137403B1 (en) 1998-12-11 2009-03-11 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
WO2001008672A2 (en) 1999-02-12 2001-02-08 G.D. Searle & Co. Glucamine compounds for treating hepatitis virus infections
ES2311921T3 (es) * 1999-02-12 2009-02-16 United Therapeutics Corporation N-(8,8,8-trifluorooctil)1-5,-didesoxi-1,5-imino-d-glucitol para tratar infecciones por el virus de la hepatitis.
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
AU783656B2 (en) 1999-09-02 2005-11-24 Nostrum Pharmaceuticals, Inc. Controlled release oral dosage suitable for oral administration
US7235258B1 (en) 1999-10-19 2007-06-26 Nps Pharmaceuticals, Inc. Sustained-release formulations for treating CNS-mediated disorders
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
GB2356346A (en) * 1999-11-19 2001-05-23 Mars Uk Ltd Food product for oral delivery of a pharmaceutical agent to a non-human animal comprising encapsulated particles of said agent distributed within the product
WO2001060366A1 (en) * 2000-02-14 2001-08-23 Pharmacia Corporation Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
JP2008510835A (ja) 2004-08-25 2008-04-10 エッセンシャリス，インク． カリウムａｔｐチャンネル開放因子の製剤処方、及びその使用
WO2006065792A2 (en) * 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using cannabinoid analogs
WO2006065793A2 (en) 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR,10aR)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
WO2007081521A2 (en) 2006-01-05 2007-07-19 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
CA2671197A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system
CN101795691A (zh) * 2007-07-02 2010-08-04 伊森舍丽斯有限公司 钾atp通道开放剂的盐及其用途
WO2012048045A1 (en) * 2010-10-05 2012-04-12 Jb Therapeutics, Inc. Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
WO2013130411A1 (en) 2012-02-27 2013-09-06 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
KR20160002709A (ko) 2013-02-12 2016-01-08 코버스 파마수티컬스, 아이엔씨. 초고순도 테트라하이드로카나비놀-11-오익산
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
KR102323613B1 (ko) 2014-11-14 2021-11-09 에센셜리스 인코포레이티드 프라더-윌리 증후군 또는 스미스-마제니스 증후군을 가지는 대상체를 치료하는 방법
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
NL2022614B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical, phyto-cannabinoid based compositions
NL2022616B1 (en) 2019-02-21 2020-09-18 Patrick Alexander Unger Cannabigerol and pharmaceutical compositions comprising cannabigerol for use in the treatment of insomnia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809917A (en) * 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical tablets
US2809916A (en) * 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
US3402240A (en) * 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
US3148124A (en) * 1962-06-12 1964-09-08 William E Gaunt Method of preparing sustained release pharmaceutical tablets
US3279998A (en) * 1962-06-22 1966-10-18 Smith Kline French Lab Method of preparing sustained release tablets
GB1021924A (en) * 1962-06-22 1966-03-09 Smith Kline French Lab Improvements in or relating to method of preparing sustained release tablets
GB1033484A (en) * 1963-06-28 1966-06-22 Mead Johnson & Co Process for preparing tablets containing chloral betaine
US3400197A (en) * 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
GB1137379A (en) * 1967-10-26 1968-12-18 Dow Chemical Co Pharmaceutical preparation
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
GB1333576A (en) * 1970-10-21 1973-10-10 Alza Corp Sustained release drug dosage device
GB1405088A (en) * 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3962414A (en) * 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
FR2250793B1 (es) * 1973-11-09 1978-12-29 Commissariat Energie Atomique
US3946110A (en) * 1974-05-30 1976-03-23 Peter, Strong Research And Development Company, Inc. Medicinal compositions and methods of preparing the same
EP0013131A3 (en) * 1978-12-27 1981-01-07 Mundipharma A.G. Pharmaceutical composition in solid dosage form, and process for its production
FI63335B (fi) * 1979-02-02 1983-02-28 Orion Yhtymae Oy Foerfarande foer framstaellning av tabletter med foerdroejd loslighet av effektaemne
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
DE3218150C2 (de) * 1982-05-14 1986-09-25 Akzo Gmbh, 5600 Wuppertal Wirkstoff enthaltender Körper für die Langzeitabgabe sowie Verfahren zu dessen Herstellung
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤

Also Published As

Publication number Publication date
US4880830A (en) 1989-11-14
DE3771091D1 (de) 1991-08-08
DK175055B1 (da) 2004-05-10
FI91482B (fi) 1994-03-31
ATE64849T1 (de) 1991-07-15
NO870558L (no) 1987-08-14
JPS62215519A (ja) 1987-09-22
JPH0655669B2 (ja) 1994-07-27
PH25347A (en) 1991-05-13
GR3002822T3 (en) 1993-01-25
EP0235986B2 (en) 1999-04-21
DK74187A (da) 1987-08-14
FI870588A7 (fi) 1987-08-14
GR3030706T3 (en) 1999-11-30
NO870558D0 (no) 1987-02-12
DK74187D0 (da) 1987-02-13
ZA871030B (en) 1988-04-27
NO175240C (no) 1998-02-10
FI870588A0 (fi) 1987-02-12
EP0235986B1 (en) 1991-07-03
GB2186485A (en) 1987-08-19
AU589254B2 (en) 1989-10-05
AU6877687A (en) 1987-08-20
GB8603523D0 (en) 1986-03-19
FI91482C (fi) 1997-05-27
IE59451B1 (en) 1994-02-23
GB2186485B (en) 1988-09-07
EP0235986A1 (en) 1987-09-09
IE870332L (en) 1987-08-13
NO175240B (no) 1994-06-13
ES2029269T3 (es) 1992-08-01

Similar Documents

Publication Publication Date Title
ES2029269T3 (es) Un metodo de fabricacion de una formulacion de liberacion lenta.
ES2054716T3 (es) Bis-naftalimidas, su obtencion y empleo.
ES459938A1 (es) Procedimiento para obtener una composicion farmaceutica en forma de un gel de polimero carboxivinilico, para insercion en el cuerpo
MX9205920A (es) Formulacion farmaceutica en polvo, de liberacion controlada
DE3778223D1 (de) Biologisch erodierbares system mit gesteuerter freisetzung des arzneiwirkstoffes.
ES2173096T3 (es) Composicion farmaceutica peletizada.
ES2035259T3 (es) Compuesto absorbente.
ES8705222A1 (es) Procedimiento para preparar una dispersion acuosa estable, congelada, de un copolimero y una droga. (como desglose y con prioridad de la patente espanola no. 544.580, presentada el 26 de junio de 1.985).
PT93170A (pt) Processo para a preparacao de dispositivos distribuidores nomeadamente de capsulas contendo um ingrediente activo
ES2128369T3 (es) Procedimiento para la fabricacion de formas farmaceuticas solidas con liberacion prolongada en dos etapas.
ES8307845A1 (es) Procedimiento para preparar una polilactida.
PT83572B (pt) Processo para a preparacao de compostos heterociclicos de quinoxalina e de composicoes farmaceuticas que os contem
ES2043671T3 (es) Una composicion para aplicacion a un sitio vegetal.
ES491307A0 (es) Un procedimiento para la preparacion de una composicion de liberacion controlada de un compuesto biologicamente activo para su administracion a un animal
ATE68686T1 (de) System zum freigeben von stoffen in der vagina.
ES2053528T3 (es) Composicion farmaceutica que comprende un medicamento y un polimero hinchable en agua.
ES2062997T3 (es) Vinilcefalosporinas sustituidas, procedimiento para su fabricacion y su uso como medicamento.
MX173572B (es) Matriz de espuma activa artropodicidalmente, estable, soluble en agua y metodo para su preparacion
ES2061550T3 (es) Vinilcefalosporinas substituidas, procedimiento para su preparacion y su uso como medicamento.
ES2053506T3 (es) Composiciones de resina pesticida mas seguras para controlar plagas del suelo y procedimiento para su preparacion.
JPS57142913A (en) Donor of physiologically active substance
JPS5282715A (en) Long acting drug composition
JPS5441321A (en) Remedy for skin diseases and its preparation
ES472528A1 (es) Procedimiento para la preparacion de derivados de benzosul- fonamida
YU47887B (sh) Postupak za pravljenje čvrstog farmaceutskog preparata za oslobadjanje aktivne supstance

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 235986

Country of ref document: ES